Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

Gut

Volumn 46, Issue 1, 2000, Pages 107-113

  Mutimer, D ^a   Shaw, J ^a   Hubscher S ^a   Elias, E ^a   Pillay, D ^b   Shields, P ^a   Cane, P ^b   Ratcliffe, D ^b   Martin, B ^b   Buchan, S ^b   Boxall, L ^c   O'Donnell, K ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Hepatitis B virus; Lamivudine; Prophylaxis; Reinfection

Indexed keywords

FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HYPERIMMUNE GLOBULIN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DNA SEQUENCE; DRUG EFFICACY; DRUG MONITORING; FEMALE; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; REINFECTION; STRUCTURAL GENE; VIRUS REPLICATION; VIRUS TITRATION;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 0034068988     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.1.107     Document Type: Article

References (18)

1. 1 Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
2. 2 Lai C-L, Ching C-K, Tung A K-M, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled study. Hepatology 1997;25:241-4.
3. 3 Grellier L, Mutimer DJ, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-15.
4. 4 Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995;345:396-7.
5. 5 Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-13.
6. 6 Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-17.
7. 7 Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after liver transplantation. Lancet 1997;349:20-2.
8. 8 Honkoop P, Niesters HGM, de Man RAM, et al. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol 1997;26: 1393-5.
9. 9 Lai CL, Liaw YF, Leung NWY, et al. 12 months of lamivudine (100mg od) therapy improves liver histology: results of a placebo controlled multicentre study in Asia. J Hepatol 1997;26(suppl 1):79.
10. 10 Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B [abstract]. Hepatology 1996;24:188A.
11. 11 Mutimer DJ, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999;30:715-21.
12. 12 Kruger M, Tillmann HL, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplantation and Surgery 1996;2:253-62.
13. 13 Gish RG, Lau JYN, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996;23:1-7.
14. 14 McCaughan G, Angus P, Bowden S, et al. Retransplantation for pre-core mutant related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy. Liver Transplantation and Surgery 1996;2:472-4.
15. 15 Nauomov NV, Chokshi S, Smith HM, et al. Emergence and characterisation of lamivudine-resistant hepatitis B virus variant [abstract]. Hepatology 1996;24:282A.
16. 16 Tipples GA, Ma MM, Fischer KP, et al. Mutation of HBV RNA-dependant DNA polymerase confers resistance to lamivudine in vivo [abstract]. Hepatolagy 1996;24:283A.
17. 17 Gutfreund KS, Fischer KP, Tipples G, et al. Late breakthrough of HBV viraemia with lamivudine as a single agent for prevention of graft reinfection in liver transplantation for cirrhosis secondary to hepatitis B [abstract]. Hepatology 1996;24:285A.
18. 18 Aye TT, Bartholomeusz A, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-53.